Inbiomotion, a great example of tech transfer by Roger Gomis
The Science Blog “Eduscopi” publishes an interview with ICREA researcher Roger Gomis, leader of the Growth Control and Cancer Metastasis Lab at IRB Barcelona and founder of Inbiomotion, a spin-off of IRB Barcelona and ICREA, launched in 2011.
Roger Gomis set up Inbiomotion with the aim to develop biomarkers to predict bone metastases from biopsies of primary tumors. During the interview, he explains what creating a spin-off is all about, laying special emphasis on social return on investment.
Link to Eduscopi
Related content
News
Israel Ramos is a drug discovery professional specialised in in vitro assay development support to research programs and compound characterisation. With his more than 15 years of experience in the pharmaceutical industry, he is currently working at the at IRB Barcelona Innovation department as Technology Transfer Consultant. Israel provides support to IRB Barcelona researchers by giving advice about the applicability of potential drug candidates based on IRB Barcelona discoveries.
It is estimated that one in four people will require brain treatment at some point. While there are drug candidates for most diseases of the brain, the blood-brain barrier (BBB) poses an impassable obstacle for most of these compounds and a bottleneck for the delivery of drugs that could cure these patients.
Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB). The company has launched a project to develop a therapeutic strategy, designed by IBEC, to treat solid tumours, which account for 90-95% of cancer cases.
